Reduction of Non-endothelial Cell Contamination of Microvascular Endothelial Cell Seeded Grafts Decreases Thrombogenicity and Intimal Hyperplasia  by Arts, C.H.P. et al.
Eur J Vasc Endovasc Surg 23, 404–412 (2002)
doi:10.1053/ejvs.2002.1604, available online at http://www.idealibrary.com on
Reduction of Non-endothelial Cell Contamination of
Microvascular Endothelial Cell Seeded Grafts Decreases
Thrombogenicity and Intimal Hyperplasia
C. H. P. Arts∗1,2, J. D. Blankensteijn1, G. J. Heijnen-Snyder1,2, H. J. M. Verhagen1,
P. Ph. A. Hedeman Joosten1, J. J. Sixma2, B. C. Eikelboom1 and P. G. de Groot2
Department of 1Vascular and Transplantation Surgery and 2Thrombosis and Haemostasis Laboratory,
Department of Haematology, University Medical Center, Utrecht, The Netherlands
Introduction: fat derived microvascular endothelial cells (MVEC) seeded on prosthetic vascular grafts, improve patency
in animals. Results in humans were disappointing, due to thrombogenicity and progressive intimal hyperplasia. Also in
animals intimal hyperplasia was found. We postulate that contaminating cells present in the transplant are involved in
the intimal hyperplasia. We developed a method to further purify human MVEC from 40–90%. Here we tested the effects
of enrichment upon thrombogenicity and seeding-related intimal hyperplasia.
Methods: liposuction fat was enzymatically digested and centrifuged. To enrich MVEC, contaminating macrophages
and fibroblasts were removed with dynabeads coated with macrophage- and fibroblast-specific antibodies. Thrombogenicity
was assessed by measuring tissue factor and thrombomodulin activity, presence of endothelial nitric oxide synthase and
via perfusion of the cells with whole blood. To investigate seeding-related intimal hyperplasia, PTFE grafts were seeded
with the cells and cultured for 3 weeks.
Results: tissue factor activity of purified cells was reduced compared to nonpurified cells. Purified cells showed
thrombomodulin activity and eNOS expression. Fragment 1+2 and Fibrinopeptide A generation after perfusion of
purified cells were significantly lower than after perfusion of nonpurified cells, and only nonpurified cells were covered
with platelets and fibrin. Prostheses seeded with nonpurified cells showed an EC monolayer above a multilayer of
myofibroblasts, prostheses seeded with purified cells only showed a single EC monolayer. Mixing experiments with human
umbilical cord EC (HUVEC) and fibroblasts showed that when more than 25% HUVEC were present a confluent EC
layer was formed. When the amount of fibroblasts was 25% or less, no development of a subendothelial multilayer of
myofibroblasts was found within 3 weeks.
Conclusion: reduction of non-endothelial cell contamination of microvascular endothelial cell seeded grafts decreases
thrombogenicity and might prevent seeding-related intimal hyperplasia.
Key Words: Microvascular endothelial cells; Cell seeding; Dynabeads; (Myo)fibroblast-like cells; Macrophages; Thrombo-
genicity; Intimal hyperplasia.
Introduction of cells,6 and that the proliferation rate of human EC
is low.7
The patency of small diameter prosthetic vascular In principle, two strategies have been introduced to
grafts in humans is low due to the thrombogenicity increase the amount of EC: in vitro endothelialisation
of the material and the lack of spontaneous endo- of grafts and finding a more abundant source of EC.8
thelialisation. Seeding of vascular grafts with endo- Promising results have been obtained with in vitro
thelial cells (EC) has been developed to improve endothelialised PTFE grafts.9 A disadvantage is the
patency.1,2 In contrast to studies in dogs, initial results necessity of a 4-week culture period which requires
of studies in humans have been inconsistent.3–5 The the patient to undergo an additional operation, and
main problems were that the EC yield from human increases the risk of infection.8,10
veins is too low to seed a graft with a confluent layer Subcutaneous fat tissue is a source of large amounts
of microvascular EC (MVEC), and in vitro culturing is
not necessary. The results of animals studies were
∗ Please address all correspondence to: C. H. P. Arts, Department promising,11 however, clinical trials in humans haveof Surgery (G04.228), University Medical Center Utrecht, P.O. Box
85500, 3508GA Utrecht, The Netherlands. shown inferior results as compared to the in vitro
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endothelialisation procedure using veins.6,12–14 Pro- fetal calf serum/4 g/ml fungizone (Gibco BRL)/100
IU/ml penicillin/100 g/ml streptomycin (Gibcogressive concentric intimal thickening, sometimes to-
gether with thrombosis was found in the grafts.12,13,15 BRL)/sodiumpyruvate (Gibco BRL)/non-essential
amino acids (Gibco BRL). Cells of the 5–7th passageIntimal hyperplasia was also found when the grafts
were tested in animals, but to a lesser extent.16,17 In an were used.
earlier animal study, we found that the myofibroblasts
in the intimal hyperplasia originated predominantly
from contaminants of the seeded cell population.18
Effect of purification with regard to thrombogenicityIn human MVEC isolates, (myo)fibroblast-like cells
or pericytes and macrophages were found as con-
Tissue factor activitytaminating cells.6,19–22 We have developed an additional
Nonpurified, purified and removed cells (2.105/cm2)purification step to deplete these fibroblasts and
and HUVEC (2.104/cm2) were grown in 48-wells plates.macrophages, resulting in a cell population of 90%
Previous publications have shown that for cells im-MVEC.23
mediately after isolation, a seeding density of 2.105The aim of this study was to investigate the effect
needs to be chosen, because the initial adherence ofof purification of MVEC isolates upon thrombogenicity
these EC ranges from 10 to 40 percent of the appliedand intimal hyperplasia in in vitro models.
EC.17,27 For HUVEC we have used a density based on
the number of cells/cm2 culture flask. Tissue factor
activity was measured as described before (factor Xa
Methods generation assay).28 The reaction was stopped after
15 min. To quantify tissue factor activity, a calibration
Isolation and purification of MVEC curve was made using different dilutions of tissue
factor (Innovin) (Baxter, Unterschleissheim, Germany)
Nonpurified and purified MVEC were isolated as de- under the same conditions as used for factor Xa gen-
scribed before.23 Nonpurified, purified and removed eration on EC. Tissue factor was expressed as dilution
cells were counted and seeded on human fibronectin- of Innovin (arbitrary units, 1 unit is defined as 1000/
coated culture plates, glass coverslips, Thermanox⊂ dilution of Innovin).
coverslips or polytetrafluoroethylene (ePTFE) grafts.
Cells were cultured in EBM-MV2 Bulletkit culture Thrombomodulin activity
medium (EBM-2 supplemented with EGM-2-MV Purified MVEC (2.105/cm2) and HUVEC (2.104/cm2)
SingleQuots containing hEGF, hydrocortisone, fetal were grown in 48-wells plates. As soon as the cells
bovine serum, VEGF, hFGF-B, R3-IGF-1, Ascorbic had reached confluence, half of the wells were in-
Acid, GA-1000) (Clonetics, BioWhittaker, Verviers, Bel- cubated with 29 g/ml mouse monoclonal antibody
gium) with 0.5 M cAMP (Sigma).24 against thrombomodulin (DAKO) (1 h). Protein C ac-
tivation was measured as described before.29 Throm-
bomodulin activity was determined by subtraction the
results of Protein C activation obtained after pre-Human umbilical cord endothelial cells (HUVEC)
treatment with anti-thrombomodulin antibody from
results obtained without pre-treatment with anti-HUVEC were isolated according to Jaffe et al.25 with
thrombomodulin antibody. To quantify thrombo-some minor modifications26 and cultured in EBM-2
modulin activity a calibration curve was made withBulletkit culture medium (EBM-2 supplemented with
different dilutions of purified thrombomodulin (Amer-EGM-2 SingleQuots (hEGF, hydrocortisone, fetal bo-
ican Diagnostica, Greenwich, CT, U.S.A.).vine serum, VEGF, hFGF-B, R3-IGF-1, Ascorbic Acid,
GA-1000, heparin) (Clonetics). Second or third passage
eNOS expressioncells were used.
Purified cells were grown on a fibronectin-coated
coverslips (105/cm2). After confluence, cells were
fixed fixed with 3% PFA in RPMI buffer (0.1 g/l
Ca(NO3)2.4H2O, 0.4 g/l KCl, 0.1 g/l MgSO4.7H2O,Fibroblasts
0.6 g/l NaCl, 2 g/l NaHCO3, 0.8 g/ Na2HPO4; pH 7.4),
and quenched for free aldehyde groups with 20 mMHuman fetal lung fibroblasts (MRC) were used (Bio-
whittaker) and cultured in minimum essential medium NH4Cl. Cells were then incubated with 5% normal goat
serum/0.1% saponin (30 min), followed by incubation(Gibco BRL, Life Technologies, Paisley, Scotland)/10%
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with mouse anti-human eNOS (Transduction Laborat- Tween, pH 7.4), for the calibration curve, were mixed
with an equal volume of sheep anti-FPA, affinity puri-ories, Becton Dickinson, Lexington, KY, U.S.A.). For
visualisation cells were stained with FITC-conjugated fied IgG (Kordia) (1 g/ml in HBS-BSA-T20 buffer).
Hundred l of this mixture was added to the plategoat anti-mouse. Cells incubated without the first anti-
body were used as a control. Examination was per- after four wash steps with 0.1% Tween in PBS and
incubated overnight at 4 °C. The plate was rinsed forformed with confocal laser microscope (Leica TCS nt,
Leica, Heidelberg, Germany). another four times with 0.1% Tween in PBS and 100 l
rabbit anti-sheep, affinity purified IgG, peroxydase
Perfusion of confluent cell layers with whole blood conjugated (Kordia) (0.5 g/ml in HBS-BSA-T20 buf-
Nonpurified, purified and removed cells (105/cm2) fer) was added and incubated for 1 h at room tem-
and HUVEC (104/cm2) were seeded on thermanox⊂ perature. After four wash steps, the plate was
coverslips. When confluence was reached, cells were developed with OPD substrate and absorbence was
perfused with anti-coagulated blood (20 U/ml final measured (490 nm, endpoint measurement) in a Vmax
concentration low molecular weight heparin) under kinetic micro plate reader.
non-pulsatile flow conditions using a modified small
perfusion chamber.30 After 5 min flow (shear rate of F 1+2 generation. F 1+2 was measured by a com-
300 s−1) the perfusate was collected in 10 mM final mercially available immunoenzymoassay (Enzygnost
concentration EDTA. Samples were taken and stored F 1+2, Behring, Germany) according to the in-
at −20 °C. structions of the manufacturer.
Light microscopy. Coverslips were rinsed with a Hepes
buffer (10 mM Hepes, 145 mM NaCl, pH 7.35) and
fixed with PBS/0.5% glutardialdehyde (30 min).
Seeding of ePTFE graftsCoverslips were incubated with methanol (5 min)
and stained with May–Gru¨nwald twofold diluted in
Standard ePTFE grafts with a length of 4 cm wereSo¨rensen buffer (1.58 mM KH2PO4, 1.75 mM Na2H-
used. On both ends of sterilised grafts luerlock con-PO4.2H2O, pH 6.9) (3 min) and Giemsa eight-fold di-
nectors were attached. One hour before cellseeding,luted in So¨rensen buffer (15 min). Slides were rinsed
the grafts were filled under pressure, one end closed,with aquadest and mounted.
with PBS to replace trapped air in the interstices of
the graft. Then the graft was filled under pressureFPA generation. FPA was measured by enzyme linked
with 50 g/ml human fibronectin. Incubation was per-immune sorbent assay (ELISA) according to a protocol
formed for one hour at 37 °C.of Affinity Biologicals Incorporated (director Hugh
Before seeding the prostheses were washed withHoogendoorn), Hamilton, Canada, with the exception
PBS and medium under pressure. Nonpurified, puri-that we used bentonite instead of ethanol precipitation
fied and removed cells were seeded. As a control,to extract fibrinogen from plasma.31 Small adaptations
HUVEC, fibroblasts and different combinations of HU-were performed after personal communication with
VEC and fibroblasts (HUVEC:fibroblasts: 100%, 75/Dr. J. M. Stassen, PhD, Dept. of Cardiovascular and
25, 50/50, 25/75 and 0/100) were used. The cell sus-Metabolic Research, Boehringer Ingelheim Pharma
pension (2.105/cm2) was introduced into the graft withKG, Biberach an der Riss, Germany. A 96-wells plate
a syringe from bottom to top. Subsequently, medium,(Immulon-4 microtiterplates, Dynex, Breda, The Neth-
four times the volume of the graft, was forced througherlands) was coated with 100 l synthetic FPA (Bachem,
the graft in about 1 min. After half an hour, the periodBubendorf, Switzerland) (10 g/ml in 50 mM Na2CO3,
that normally elapses between seeding and graft im-pH 9.5) at 4 °C. After overnight incubation the plate
plantation in vivo, both ends were cut off and the graftwas blocked for 2 h at RT with PBS/2%BSA (Boseral,
was opened longitudinally and fixed in the siliconKordia). In the meantime plasma samples were treated
coated glass petri dishes with small needles. Culturewith one half of their volume bentonite (Sigma) (0.5 g/
was performed for 212–3 weeks.5 ml TSO buffer (0.5 M Tris, 0.10 M NaCl, pH 8.9; 0.1%
ovalbumin)) on a roller bank for 10 min at RT, to
remove fibrinogen.31 Plasma/bentonite samples were Histopathology and immunohistochemistry
Paraffin slides were made for haematoxylin and eosincentrifuged (10 000 rpm, 10 min) and supernatants
were transfered to clean 1.5 ml tubes. Plasma/ben- (HE) and immunohistochemical stains. Pro-celloidin
moistened with 35% ethanol (Sigma) was used to keeptonite sample and dilutions of FPA in HBS-BSA-T20
buffer (10 mM Hepes, 0.15 M NaCl, 1% Boseral, 0.1% the graft material fixed on the slides during staining.
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In short, during deparafinisation, after the ethanol
100% steps, slides were brought in and out the celloidin
1% in ethanol/ether 1:1 in vertical direction. Slides
were dried for 30 s, and brought in ethanol 70%.
Immunohistochemical stainings were preceded by
endogenous peroxidase blocking and citrate boiling.
Endogenous peroxidase blocking was performed
with 1.5% H2O2 in phosphate-citrate buffer (citric
acid mono-hydrate 8.32 g/l, Na2HPO4 21.52 g/l;
pH 5.8±0.1) for 15 min. Citrate boiling was done in
citrate buffer (Na3citrate dihydrate 2.94 g/l; pH 6.0) for
10 min.
The primary antibodies which were used were
mouse anti-human vWF, mouse anti-human CD31,
mouse anti-human (-actin, mouse anti-human vi-
mentin (DAKO). Peroxidase/DAB staining were done
with Vectastain Elite ABC Kit and DAB kit for per-
oxidase staining (Vector Laboratories, Burlingame,
Fig. 1. Presence of eNOS in MVEC purified with the depletionCA, U.S.A.), according to the manufacturers’ re-
method. Cells were stained with mouse anti-human eNOS antibody
commendations. followed by staining with a FITC-conjugated goat anti-mouse anti-
body (magnification, ×510).During dehydration, after the ethanol 100% steps,
slides were brought in ethanol:ether 1:1 for 5′ to remove
celloidin, after which further dehydration and mount-
ing with depex were performed. (3.1–3.8)×105/g fat (n=6). Of these purified cells, 91
For each cell type, the mean intimal thickness was (89–93)% (n=6) were EC. Of the cells removed by the
determined by measuring the thickness on a regular beads, 10 (8–14)% (n=6) were EC.
distance with a light microscope equipped with a JAC-
CCD camera (Copenhagen, Denmark) coupled to a
matrox frame grabber (Matrox Electronic systems Ltd.,
Quebec, Canada) using Optimas 6.0 software (DVS, Effect of purification with regard to thrombogenicity
Breda, The Netherlands).
Tissue factor activity
Tissue factor activity of purified cells, 0 (0–0.06) ar-
bitrary units (n=50 out of 5 different isolations), was
Statistical analysis significantly reduced (p<0.001) compared with non-
purified cells, 1.14 (0.77–1.45) arbitrary units (n=50
Results are presented as the median (1st–3rd quartile out of 5 different isolations). Tissue factor activity of
range). A non-parametric test was used to determine removed cells, 1.22 (0.87–1.52) arbitrary units (n=50
significant differences between groups (Mann– out of 5 different isolations), was slightly higher than
Whitney U-test). A p-value <0.05 was considered sig- that of nonpurified cells. Tissue factor activity HUVEC
nificant. was not detectable (n=30 out of 3 different isolations).
Thrombomodulin expression and activity
Thrombomodulin activity of purified MVEC was 44.9Results
(21.8–72.2) fmol/cm2 (n=20 out of 5 different isol-
ations), similar (p=0.331) to that of HUVEC, whichPurification of microvascular endothelial cells
was 46.8 (24.7–67.6) fmol/cm2 (n=20 out of 5 different
isolations).After enzymatic digestion and centrifugation the yield
of nonpurified cells was 10.0 (9.0–11.7)×105/g fat (n=
6). Of these nonpurified cells, 41 (34–42)% (n=6) were ENOS expression
MVEC stained positive for eNOS (Fig. 1). Omission ofEC, as determined with CD31-expression using flow
cytometry. After purification with F11-/CD14-coated the anti-eNOS antibody did not result in a positive
staining.dynabeads the yield of purified cells was 3.2
Eur J Vasc Endovasc Surg Vol 23, May 2002
C. H. P. Arts et al.408
Fig. 2. Confluent cell layers after perfusion with LMWH-anti-coagulated blood. Stainings were performed with Giemsa and May–Gru¨nwald
(magnification, ×480). (a) HUVEC. (b) Purified cells. (c) Nonpurified cells. (d) Removed cells.
Perfusion of confluent cell layers with whole blood different isolations, perfused with blood from 3 dif-
ferent other donors), and after perfusion of removed
Light microscopy cells, 12.2 (5.3–14.3) nM (n=27 out of 3 different isol-
ations, perfused with blood from 3 different otherAfter 5 min. perfusion with whole blood, no platelet
aggregates and fibrin were visible on HUVEC and donors). F1+2 generation after perfusion of purified
MVEC was significantly larger (p=0.008) than afterpurified MVEC, whereas nonpurified and removed
cells were covered both with platelets and fibrin (Fig. perfusion of HUVEC, 0.9 (0.7–2.0) nM (n=27 out of 3
different isolations, perfused with blood from 3 dif-2).
ferent other donors).
FPA generation
FPA generation after perfusion over a surface of puri-
fied MVEC was 52.7 (16.6–80.8) ng/ml (n=27 out of
3 different isolations, perfused with blood from 3 Seeding of ePTFE grafts
different other donors), significantly lower (p<0.001)
than after perfusion over a surface of nonpurified cells, Histopathology
778.4 (520.2–1047.5) ng/ml (n=27 out of 3 different The grafts seeded with purified MVEC showed a thin
isolations, perfused with blood from 3 different other cell (mono)layer. Grafts seeded with nonpurified cells
donors), and over a surface of removed cells, 1033.0 and removed cells were covered with a multilayer of
(512.0–1161.5) ng/ml (n=27 out of 3 different isol- cells. This neointima showed a variable thickness in
ations, perfused with blood from 3 different other longitudinal as well as transversal direction. The mean
donors). FPA generation after perfusion of purified thickness of the multilayer was 4.1 (3.3–5.7) m (n=
MVEC was similar (p=0.113) to that of HUVEC, 29.0 134 out of 6 different isolations) for the grafts seeded
(9.6–71.0) ng/ml (n=27 out of 3 different isolations, with purified MVEC, 13.8 (8.1–21.8) m (n=141 out
perfused with blood from 3 different other donors). of 6 different isolations) for the grafts seeded with
nonpurified cells and 13.4 (8.1–20.1) m (n=128 out
of 6 different isolations) for the grafts seeded withF1+2 generation
F1+2 generation after perfusion of purified MVEC removed cells. The mean thickness of the intima after
seeding of purified MVEC was significantly smallerwas 2.0 (1.4–2.2) nM (n=27 out of 3 different isolations,
perfused with blood from 3 different other donors), than after seeding of nonpurified and removed cells
(p<0.001).significantly lower (p<0.001) than after perfusion of
nonpurified cells, 8.4 (6.4–10.0) nM (n=27 out of 3 The grafts seeded with pure HUVEC and with the
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groups of EC, as seen after seeding of removed cells.
The grafts seeded with pure fibroblasts were covered
with a multilayer of (myo)fibroblasts.
Discussion
Seeding of grafts with EC is an old idea to improve
patency of small diameter vascular grafts.1,2 An im-
portant problem in the set-up of EC seeding studies
is the source and the amount of autologous EC neces-
sary to seed the graft with.
A very attractive source for EC is liposuction fat, as
this source can supply enough cells to immediately
cover the graft with a confluent layer of EC withoutFig. 3. The median (1st–3rd quartile range) intimal thicknesses of
additional in vitro culturing.11 The results of clinicalHUVEC:fibroblasts combinations.
studies with fat derived MVEC seeded grafts in
humans, however, have been less convincing than that
of animal studies.6,12,13,15 The problems found with thesecombination HUVEC:fibroblasts: 75/25 were covered
with a thin cell (mono)layer. The grafts seeded with fat derived MVEC were a progressive intimal hy-
perplasia and thrombotic complications.the other combinations of HUVEC and fibroblasts and
with pure fibroblasts were covered with a multilayer. Recently, we have shown that cells contaminating
the isolated EC were incorporated in the newly formedIn Figure 3 the median (1st–3rd quartile range) intimal
thicknesses of HUVEC: fibroblasts combinations are intima of the graft.18 We speculated that the presence
of these contaminants contributes to the formation ofshown.
the intimal hyperplasia. Here we have tested this
hypothesis.Immunohistochemistry
Grafts seeded with nonpurified cells were covered We have performed an additional purification step,
using cell-specific antibodies to deplete contaminatingwith a multilayer of (myo)fibroblasts (vimentin- and
most of them -actin-positive) (Fig. 4a). This multilayer cells, that increases the content of EC in the isolate
from 40–90%.23 We tested both the nonpurified andwas for the largest part covered with a EC-monolayer
(Fig. 4b). Parts of the multilayer were not covered the purified human MVEC in vitro, in thrombosis
models and a model to study intimal hyperplasia.with an EC-monolayer, but filled with groups of EC,
forming vessel-like structures (Fig. 4c). Cells present in As only antibodies specific for human antigens were
available, we could not test the consequences of puri-the covering monolayer of grafts seeded with purified
cells were vimentin-, vWF- and CD31-positive, which fication in in vivo animal models and therefore used
these in vitro models.gave them the identity of EC (Fig. 4d). Sporadically
a myofibroblast (-actin- and vimentin-positive) was We found that tissue factor activity of purified cells
was significantly reduced compared to nonpurifiedpresent in the subintimal layer. The grafts sodded
with removed cells were covered with a multilayer of cells. Thrombomodulin activity and eNOS expression
were present in purified cells. ENOS was localized in(myo)fibroblasts with scattered small groups of EC,
forming vessel-like structures. a perinuclear region, which is in accordance with
the data of Sessa et al.,32 who showed that eNOSThe grafts seeded with 100% HUVEC were covered
with a monolayer of EC, positive for the above men- is associated with the perinuclear Golgi complex in
cultured bovine aortic cells, as well as in intact bloodtioned markers. The graft seeded with HUVEC:fibro-
blasts: 75/25 were also covered with a monolayer of vessels. F1+2 and FPA generation after perfusion of
purified cells with whole blood were significantlyEC, with scattered myofibroblasts in the sublayer, as
seen after seeding of purified cells. The grafts seeded lower than after perfusion of nonpurified cells, and
only nonpurified cells were covered with platelets andwith HUVEC:fibroblasts: 50/50 were covered with a
multilayer of (myo)fibroblasts, partly covered with a fibrin. These results suggest that the thrombogenicity
of the seeded cells is primarily due to the expressionmonolayer of EC and partly filled with groups of EC,
as seen after seeding of nonpurified cells. Grafts seeded of tissue factor by the contaminating cells. Purification
of the seeded cells would result in less thrombo-with HUVEC:fibroblasts: 25/75 were covered with a
multilayer of (myo)fibroblasts with scattered small genicity.
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Fig. 4. Immunohistochemistry of cell sodded and cultured grafts (magnification, ×205). (a) Grafts sodded with nonpurified cells, the cells
present in the multilayer stained positive with mouse anti-human -actin antibody. (b) Grafts sodded with nonpurified cells, the cells
present in the covering monolayer stained positive with mouse anti-human vWF antibody. (c) Grafts sodded with nonpurified cells,
groups of cells present in the multilayer stained positive with mouse anti-human CD31 antibody. (d) Grafts sodded with purified cells,
covered with a monolayer of cells positive for mouse anti-human vWF antibody.
Prostheses sodded with nonpurified cells were HUVEC and fibroblasts the percentage of HUVEC is
75% or more, suggests that intimal hyperplasia doescovered with a EC monolayer above a multilayer of
(myo)fibroblasts, prostheses sodded with purified cells not develop from transdifferentiated EC.
Development of intimal hyperplasia can also beshowed a single EC monolayer without a multilayer
of (myo)fibroblasts. With different combinations of attributed to cells originating from both vessel ends
and from the tissue around the vessel grafts. We cannotHUVEC and fibroblasts, used as a control, we found
that to establish a confluent EC-monolayer covering exclude that this process also contributes to intimal
hyperplasia. The specific advantage of our model is,the graft, the purity of the seeded cells should be
more than 25%, and to prevent the development of however, that the individual contribution of the con-
taminants in the seeded cells to the intimal hyperplasiaa subendothelial multilayer of (myo)fibroblasts, the
purity should be at least 75%. The experiments de- can be demonstrated.
An additional advantage of all the in vitro modelsscribed here showed that the lower the number of
contaminating cells, the thinner the intima. Our in is the suitability to test the effects of gene therapy on
intimal hyperplasia and thrombogenicity.35,36 Effectsvitro experiments were performed for only 212–3 weeks,
so that the development in time of intimal hyperplasia can be measured, the procedure is much cheaper than
the use of laboratory animals and unwanted effectsfrom the remaining contaminating cells could not be
excluded. Therefore, we would recommend to seed caused by rejection, due to species differences between
the gene and the laboratory animal, are not a problem.cells with a purity as high as possible, at least 90%.
It has been postulated that cell seeding related in- The fact that after cell seeding on a prosthesis a
multilayer is formed with a confluent EC monolayertimal hyperplasia is the result of transdifferentiated
EC.33,34 The absence of intima hyperplasia when puri- on top, might explain why the major MVEC seeding
related problem is intimal hyperplasia and not throm-fied MVEC are seeded or when in a combination of
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